Computational immunogenomic approaches to predict response to cancer immunotherapies

V Addala, F Newell, JV Pearson, A Redwood… - Nature Reviews …, 2024 - nature.com
Cancer immunogenomics is an emerging field that bridges genomics and immunology. The
establishment of large-scale genomic collaborative efforts along with the development of …

Exploiting temporal aspects of cancer immunotherapy

RM Zemek, V Anagnostou, I Pires da Silva… - Nature Reviews …, 2024 - nature.com
Many mechanisms underlying an effective immunotherapy-induced antitumour response are
transient and critically time dependent. This is equally true for several immunological events …

Remodelling of the immune landscape by IFNγ counteracts IFNγ-dependent tumour escape in mouse tumour models

VWC Lau, GJ Mead, Z Varyova, JM Mazet… - Nature …, 2025 - nature.com
Loss of IFNγ-sensitivity by tumours is thought to be a mechanism enabling evasion, but
recent studies suggest that IFNγ-resistant tumours can be sensitised for immunotherapy, yet …

Monocyte infiltration is an independent positive prognostic biomarker in vulvar squamous cell carcinoma

Z Abdulrahman, KE Kortekaas, MJP Welters… - Cancer Immunology …, 2024 - Springer
Background Vulvar squamous cell carcinoma (VSCC) arises after an HPV infection or the
mutation of p53 or other driver genes and is treated by mutilating surgery and/or (chemo) …

Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma

G Ji, Q Yang, S Wang, X Yan, Q Ou, L Gong, J Zhao… - Genome Medicine, 2024 - Springer
Background The efficacy of neoadjuvant chemo-immunotherapy (NAT) in esophageal
squamous cell carcinoma (ESCC) is challenged by the intricate interplay within the tumor …

[HTML][HTML] TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy

S Wang, Y **ong, Y Zhang, H Wang… - … for Immunotherapy of …, 2024 - ncbi.nlm.nih.gov
Background Immunotherapies targeting immune checkpoints have gained increasing
attention in cancer treatment, emphasizing the need for predictive biomarkers. Circular …

The real-world data of immune-checkpoint inhibitor combination therapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study

S Sato, T Ssuzuki, T Chinen, H Yamaguchi… - International Journal of …, 2024 - Springer
Background The real-world efficacy, feasibility, and prognostic factors of immune-checkpoint
inhibitor combination therapy for unresectable or metastatic esophageal cancer are not fully …

Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy

S Kumagai, S Koyama, K Shitara - Cancer Cell, 2023 - cell.com
Studies have established immunochemotherapy as the first-line treatment for advanced
esophageal cancer. Chen et al. and Carrol et al. performed exploratory analysis of the …

Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma

J Yates, C Mathey-Andrews, J Park, A Garza… - …, 2024 - pmc.ncbi.nlm.nih.gov
Esophageal adenocarcinoma (EAC) is a highly lethal cancer of the upper gastrointestinal
tract with rising incidence in western populations. To decipher EAC disease progression and …

The role of the fibroblast in Barrett's esophagus and esophageal adenocarcinoma

H Zhu, RU ** - Current Opinion in Gastroenterology, 2024 - journals.lww.com
Current Opinion in Gastroenterology Log in or Register Subscribe to journalSubscribe Get
new issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …